FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Early YOLT-202 data from YolTech Therapeutics suggests gene editing could redefine Alpha-1 Antitrypsin Deficiency treatment. Read the analysis.
Enveric Biosciences reports new EB-003 signaling data. Find out what this means for non-hallucinogenic antidepressant development and regulatory risk.
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
Devonian Health Group reports human liver-on-a-chip data for Thykamine in MASH. See what this means for fibrosis-focused drug development.
KilgourMD’s phase II data challenges how menopause-related hair loss is studied and treated. See what changes and what clinicians will watch next.
Discover how Molecular Instruments’ ambient-temperature HCR Pro RNA-ISH on BOND-III could reshape clinical pathology automation and RNA diagnostics.
Seek Labs secures USDA funding for a CRISPR-based avian flu therapeutic. Find out why mutation-resistant platforms may redefine HPAI response.